Nourianz

(Istradefylline)

Nourianz

Drug updated on 11/14/2023

Dosage FormTablet (oral; 20 mg, 40 mg)
Drug ClassAdenosine receptor antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes.

Product Monograph / Prescribing Information

Document TitleYearSource
Nourianz (istradefylline) Prescribing Information.2020Kyowa Kirin Inc., Bedminster, NJ

Systematic Reviews / Meta-Analyses